News & Events

Events

NCCN National Comprehensive Cancer Network

2 FREE Webinars focusing on Myeloproliferative Neoplasms
May 1, 2018 + May 5, 2018

https://www.nccn.org/patients/webinar/default.aspx


4th annual SF Bay Area MPN Conference

October 6, 2018
4th annual SF Bay Area MPN Conference
UCSan Francisco

Sign up here

MPN Advocacy & Education International Calendar of Events

Click here to view the MPN Advocacy & Education International Calendar of Events


News

Nominate your Hero today

Since 2013, the MPN Heroes Recognition Program has recognized the people and organizations that have dedicated themselves to improving the lives of people with MPNs. The program focuses on the three “classical” MPNs—or what are known as Philadelphia chromosome–negative MPNs.

2018 marks the sixth anniversary of the MPN Heroes Recognition Program, sponsored by Incyte Corporation and CURE magazine. Our goal is to create as many opportunities as possible for people with MPNs to be heard and to be supported, so more solutions and treatment options will emerge.

Created in the spirit of fostering community, the program recognizes patients, Healthcare Professionals, caregivers, advocates, and organizations that contribute to bringing understanding, compassion, and strength to the MPN community.

www.mpnheroes.com


UT Health Cancer Center announces new director

https://news.uthscsa.edu/ut-health-cancer-center-announces-new-director/


Dr. Mesa is relocating to UT Health San Antonio Cancer Center, TX

Patient Announcement


5 year Results from the Phase 3 Study of Jakafi

http://www.businesswire.com/news/home/20160606005457/en


Living with MPNs Survey

A 30-minute survey for patients with myeloproliferative neoplasms (MPNs). A research study (sponsored by Incyte Corporation) is being conducted to learn more about the impact of MPNs on patients’ lives. Incyte is seeking patients aged 18 to 70 with MF, PV or ET to participate in a one-time, 30-minute online survey about how your condition has affected your work, finances, and quality of life. If you are eligible and complete the survey, you will be compensated.For more information, please visit https://www.surveymonkey.com/r/VXTHC37


FDA approval of Jakafi (Ruxolitnib) for the treatment of Polycythemia Vera

www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm


National Organization of Rare Diseases

Stories about 3 patients (Antje with ET, Annette with PV and Bill with MF) on the NORD website:
www.rarediseases.org/rare-disease-information/living-with-rd


MPD-RC

The MPD Research Consortium is a National Cancer Institute supported project involving 50 International MPN Centers in the United States, Canada, Europe and Israel. It is a resource for both patients and physicians focusing on advancing the science and therapy of myeloproliferative neoplasms
mpdrc.org


Are You a Vietnam Veteran?

Were you exposed to Agent Orange? Do You Have Myelofibrosis (MF), Polycythemia Vera (PV) or Essential Thrombocythemia (ET)?

MPN Advocacy and Education International is conducting a survey of Vietnam Veterans to determine how many were exposed to Agent Orange and now have a diagnosis of Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia (Myeloproliferative Neoplasms- MPNs. This information will be collected in an attempt to add myeloproliferative neoplasms to the US Department of Veterans Affairs ‘presumptive’ list of conditions resulting from exposure to Agent Orange/dioxin during the Vietnam War and could create a resource for assistance with treatments and compensation.

This is our first step in what could allow for further research into the link between myeloprliferative neoplasms and exposure to Agent Orange/dioxin.

Please contact Ann Brazeau:

abrazeau@mpnadvocacy.com